Briefing
MolDX lists Signatera for recurrence testing in non-small cell lung cancer
The MolDX billing article A58434, in the revision effective January 1, 2026, lists Signatera for the diagnosis of recurrence or relapse in patients with a personal history of non-small cell lung cancer.